Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
dPD-1 hCD19CART in Refractory Aggressive B-cell NHL
ChiCTR-OIC-17011310Phase 2Recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Jun 2017
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dPD-1 + hCD19CART in non-Hodgkin lymphoma (NHL), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: Objective remission rate. Started Jun 2017; status: recruiting.
02
Drugs
dPD-1 + hCD19CART
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on ChiCTR-OIC-17011310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OIC-17011310.